Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Diabetic Nephropathy
Interventions
DRUG

VPI-2690B low dose

Comparison of different doses of study drug

DRUG

VPI-2690B medium dose

Comparison of different doses of study drug

DRUG

Placebo to match VPI-2690B

DRUG

VPI-2690B high dose

Comparison of different doses of study drug

Trial Locations (34)

Unknown

Birmingham

Little Rock

La Mesa

Riverside

Sacramento

Tustin

Cooper City

Coral Springs

Hialeah

Miami

St. Petersburg

Winter Park

Columbus

Idaho Falls

Mount Prospect

Peoria

Merrillville

Boston

Flint

Kansas City

Las Vegas

Albany

Asheville

Greenville

Morehead City

Winston-Salem

Cincinnati

Wooster

Allentown

Nashville

El Paso

San Antonio

Ponce

San Juan

All Listed Sponsors
lead

Vascular Pharmaceuticals, Inc.

INDUSTRY

NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients | Biotech Hunter | Biotech Hunter